Zu den Inhalten springen

International Medical Services & Business Development

Official Site of the Medical Center – University of Freiburg

Kontextnavigation:

Nuclear Medicine

The Department of Nuclear Medicine uses radiopharmaceuticals for diagnostics and treatment of various diseases with particular emphasis on endocrine, cancerous and neurological diseases. While diagnostic procedures can be performed on an out-patient basis, most treatments with radioactive substances are done on an in-patient basis to achieve optimal results and to comply with German radiation protection law.

More than 3.000 PET-CTs are conducted on modern scanners (16- and 64-slice CT and time-of-flight PET imaging especially important for planning radiation therapy) for various oncological, neurological and cardiological diseases.

Some of our ultra-modern specialties are radioligand therapy for cancer treatment, DOTATE therapy and SIRT. We also offer the full range of modern nuclear diagnostics and therapies for benign and malignant thyroid diseases and organ scintigraphy (including SPECT and SPECT/CT).

The Department of Nuclear Medicine of the Medical Center - University of Freiburg is licensed as a training center for nuclear medicine by the European Board of Nuclear Medicine.

 


Diagnostic & Treatment Services

  • Highly specialized clinic for benign and malignant thyroid diseases, offering the full spectrum of modern diagnostic and therapeutic options
  • PET/CT (2 modern PET/CT systems: 16- and 64-slice CT and time-of-flight PET imaging) with numerous molecular imaging probes for:

    • Oncology: Detection, staging and treatment monitoring of cancer, in particular lung cancer, lymphoma, gastrointestinal malignancies, prostate cancer, melanoma, neuroendocrine tumors and brain tumors. Molecular imaging targets include glucose, protein and cell membrane metabolism and transport, cell proliferation, prostate-specific membrane antigen (PSMA), hormone receptors, perfusion and hypoxia. PET-based radiation treatment planning, especially for stereotactic and intensity modulated radiotherapy.
    • Neurology: State-of-the-art diagnostics, differential diagnostics and follow-up of neurodegenerative disorders, most notably including dementia (e.g., Alzheimer’s disease) and movement disorders (e.g., Parkinson’s disease, Huntington’s disease). Localization of epileptogenic foci in patients with seizures. Molecular imaging target include glucose metabolism, dopamine synthesis and storage, cerebral perfusion, a variety of neurotransmitter receptors and transporters (dopaminergic and serotonergic neurotransmission) and amyloid-beta and tau imaging
    • Cardiology: Detection of viable myocardium in patients with coronary artery disease prior to revascularization

      Read more about PET/CT

  • Molecular Therapy

    • Radioiodine therapy of hyperthyroidism and goiter
    • Radioiodine therapy and targeted therapies in thyroid cancer
    • Radioligand Therapy:
      Peptide-receptor radionuclide therapy (PRRT) using Lutetium-177-labelled somatostatinreceptor ligands for the treatment of metastasized neuroendocrine tumors and Radionuclide treatment of advanced prostate cancer using Lutetium-177-labelled PSMA-ligands. Read more
    • SIRT - Selective internal radiation therapy for treatment of primary and secondary liver tumors using Yttrium-90-labeled microspheres. Read more
    • Radium-223 therapy for bone metastases of prostate cancer
    • Treatment of lymphoma with radiolabeled anti-CD20 antibodies
    • Treatment of bone pain secondary to metastases

  • Conventional scintigraphy (including SPECT and SPECT/CT) for diseases of the thyroid, skeleton, heart, lungs, kidneys, brain, assessments of the gastrointestinal tract and preoperative visualization of lymphatic drainage for sentinel lymph node resection
  • Second Opinion Service

Statistics

medical doctors12
medical physicists and radiochemists10
Radioiodine therapies per yearover 700
  • Over 3.000 PET/CT scans per year


Our team (board certified)

  • Prof. Dr. Dr. Philipp T. Meyer

    Medical Director

  • PD Dr. Juri Ruf

    Vice Medical Dirctor

  • Dr. Hans Christian Rischke

  • Dr. Christian Götz

  • Dr. Andrea Bürkle

  • M. Schulenburg

Medical Center - University of Freiburg

Phone: +49 761 270 21310
Fax: +49 761 270 19310

info-ims@uniklinik-freiburg.de